Skip to main content

LATEST WEBINAR: PSYCHEDELICS IN FOCUS

By Other newsNo Comments

In this informative webinar, we delve into the world of psychedelic trials and the evolving regulatory landscape surrounding these transformative therapies. Explore the promising efficacy of psychedelics like psilocybin, MDMA, 5-methoxy-dimethyltryptamine, and ibogaine in treating conditions such as depression, PTSD, anxiety, and substance use disorder.

During this webinar, we will:

  • Examine the diverse mechanisms of action underlying these psychedelic compounds, with a focus on serotonin 5HT2a receptor signaling.
  • Discuss the important results observed in clinical trials, showcasing the potential for durable effects lasting over a year post-dosing.
  • Highlight the pivotal role of organizations like MAPS (Multidisciplinary Association for Psychedelic Studies) in shaping the regulatory landscape for psychedelic medicines.
  • Explore the pipeline of next-generation psychedelic medicines engineered for improved pharmacodynamic and pharmacokinetic effects, reduced toxicity, and a potential for retained efficacy without the hallucinatory aspects of current psychedelic compounds.
  • Gain insights into the recent guidance issued by the US FDA and explore the regulatory pathways for the clinical study and approval of psychedelics in both Australia and the United States.

Our panel of scientists and clinicians from Australia and the US will provide invaluable insights into ongoing trials, innovations in psychedelic therapies, and the regulatory pathways shaping the future of mental health treatment.

Don’t miss this opportunity to stay informed about the latest developments in psychedelic research and regulatory advancements.

SPEAKERS:

Jorgen Mold, Senior Director of Scientific & Regulatory Services, Avance Clinical

Jorgen Mold is the Head of Scientific and Regulatory Affairs at Avance Clinical. Jorgen has worked within the clinical trial industry for over 25 years. Jorgen has prior experience as a Principal Scientific and Regulatory Affairs Specialist in a CRO environment. Additionally, Jorgen has prior experience in drug discovery and academic research positions at Northwestern University (USA), The University of Queensland and the Australian National University as well as 12 years in the biotechnology sector leading several ion channel/CNS drug discovery programs. Jorgen also spent four years working in medical affairs (neurology) at Merck Healthcare in Australia before joining Avance Clinical in August 2020.

Kevin Leach, Senior Vice President, Scientific & Regulatory Affairs, Avance Clinical

Kevin Leach has worked broadly in the biotechnology industry with hands-on experience in early and late-stage drug discovery and development. Through positions at Merck, Shire, Retrophin, Spring Bank, Quralis and Enveric as well as several other companies through consulting interactions, Kevin has worked in and led the ADME, toxicology, pharmacology, clinical pharmacology and bioanalysis functions.

Kevin has been responsible for leading discovery and development programs, the nominations of development candidates as well as multiple regulatory filings for molecules at the IND, BLA and NDA stages. He has also been part of teams that raised funding for public and private companies and has worked at mature and very early-stage companies with experience in many different indications and molecular platforms. Kevin is a member of the Boston Psychedelic Research Group and has worked on and led teams on multiple psychedelic compounds for psychiatric indications.

Kevin has recently joined Avance Clinical, an Australian and North American biotech specialist Clinical Research Organization as Senior Vice President of Scientific and Regulatory Affairs, based in Massachusetts, USA.

Who Should Watch?

This webinar will appeal to VPs, Directors, Managers, Department Heads, Scientists and Researchers working within the Biotech industry in the following areas:

  • Clinical affairs/Phase I unit
  • Clinical R&D/research
  • Clinical pharmacology/pharmacovigilance
  • Clinical operations/site selection and start-up/site management organization
  • Project management
  • Regulatory affairs
  • Medical affairs/medical research
  • Bioinformatics
  • Scientific affairs/study conduct
  • Business operations
  • Business development

What You Will Learn

Viewers will gain insights into:

  • Various psychoactive substances and promising therapeutic benefits for the treatment of psychiatric conditions
  • Explore the specific aspects of psychedelics crucial for orchestrating clinical trials
  • Examine the regulatory landscape governing novel psychedelic clinical studies in Australia
  • Delve into the outlook for emerging psychedelic compounds and their potential impact on the future

AVANCE CLINICAL STRENGTHENS ASIA-PACIFIC NETWORK WITH DIGITAL TECHNOLOGY COMPANY JNPMEDI INC

By Company NewsNo Comments

Adelaide, Australia | North Carolina, USA – Avance Clinical, the Australian and North American market-leading CRO for biotechs, has signed a strategic technology MOU with leading Korean decentralized clinical trials (DCTs) and eClinical technology company JNPMEDI Inc. The agreement expands Avance Clinical’s capabilities in the Asia-Pacific biotech clinical trials sector.

Anne Sim, Associate Director, Technology, and Innovation said, “Avance Clinical is focused on growing our networks with technology companies which offer high-quality innovative solutions designed to further accelerate the delivery of quality data to our biotech clients.

As we continue to invest in digital capacity, JNPMEDI is one company we are exploring. They are also located within the important Asia-Pacific region which really helps that relationship.”

Upon signing the MOU, Jae Hyun Lee J.D., D.D.S., Chief of Staff at JNPMEDI, expressed, “JNPMEDI is excited to partner with Avance Clinical. Korea biotech industry is an exciting and growing one, and one whose needs are uniquely answered by Avance Clinical and the Australian clinical trial market. The partnership will provide a turnkey answer to the biotech market.”

JNPMEDI’s core technology is Maven Clinical Cloud which offers a singular ecosystem for digital clinical solutions capable of streamlining activities from protocol to CSR. This ‘one stop shop’ supports subject participation while delivering efficiencies to study sites, sponsors and CROs.

The Avance Clinical Technology and Innovation team identifies and reviews the latest technology solutions including machine learning and artificial intelligence applications to support global systems integrations.

JNPMEDI and Avance Clinical connected recently at the KoNECT Korea conference in Seoul where Avance Clinical presented to over 45 Korean biotechs at a clinical trials symposium event. The presentation focused on Avance Clincial’s GlobalReady drug development acceleration solution.

The Avance Clinical team, including CEO Yvonne Lungershausen, and Vice President, Commercial Business Development, Liahna Toy shared drug development options including conducting clinical trials across Korea, Australia, New Zealand, and the United States to support fast tracking clinical trial development programs.

Andy Hu, Business Development Manager for Asia, said Avance Clinical offers two critical solutions for biotechs.

“Avance Clinical in Australia can maximize the 43.5% rebate on clinical trial spend, and in the United States can provide high quality trials following the FDA pathway. Both approaches were received as attractive propositions for biotechs wanting to maximize their data captured and conserve funding,” he said.

Liahna Toy, Vice-President, Commercial Business Development said:

“Our Avance Clinical teams in Australia and the United States offer world-class quality data and cultural alignment for Korean biotech clients designed to make their drug development programs seamless and successful.”

“Avance Clinical’s study data is accepted by all the main regulatory authorities including the MFDS and FDA; and conversely the Therapeutic Goods Administration (TGA) in Australia recognizes data generated in Korea.”

“The Korean biopharma companies we met at KoNECT Korea Conference were outstanding and we are extremely excited to be part of their clinical program as they expand to the United States.”

About Avance Clinical

Avance Clinical is a full-service CRO for biotechs with a proven track-record for delivering clinical excellence in Australia, New Zealand, and North America. As the largest premium full-service CRO in Australia and North America, Avance Clinical specializes in delivering top-tier clinical trials that yield globally accepted data.

 

Award-winning CRO for Biotechs

Avance Clinical has been recognized for the fourth consecutive year by Frost & Sullivan in 2023, being awarded the Best Practices Customer Value Leadership for Biotech’s award, for its continuous exceptional performance.

 

Pre-clinical through to Phase I and Beyond

Avance Clinical offers pre-clinical consultancy services with their experienced ClinicReady team right through to Phase I and beyond clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes that are available in Australia and highly qualified sites and networks within the United States. With experience across more than 110 therapeutic indications, Avance Clinical can deliver world-class, high-quality, internationally accepted data suitable for FDA and EMA review.

 

Technology

Avance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, Zelta, Veeva and Medrio are just some of Avance Clinical’s technology partners.

www.avancecro.com

 

Media Contact:

Avance Clinical

media@avancecro.com

 

LIVE WEBINAR: PSYCHEDELICS IN FOCUS

By Other newsNo Comments

Monday, November 27, 2023 | 10am PST / 12pm CST / 1pm EST 

Join us for an informative webinar as we delve into the world of psychedelic trials and the evolving regulatory landscape surrounding these transformative therapies. Explore the promising efficacy of psychedelics like psilocybin, MDMA, 5-methoxy-dimethyltryptamine, and ibogaine in treating conditions such as depression, PTSD, anxiety, and substance use disorder.

During this webinar, we will:

  • Examine the diverse mechanisms of action underlying these psychedelic compounds, with a focus on serotonin 5HT2a receptor signaling.
  • Discuss the important results observed in clinical trials, showcasing the potential for durable effects lasting over a year post-dosing.
  • Highlight the pivotal role of organizations like MAPS (Multidisciplinary Association for Psychedelic Studies) in shaping the regulatory landscape for psychedelic medicines.
  • Explore the pipeline of next-generation psychedelic medicines engineered for improved pharmacodynamic and pharmacokinetic effects, reduced toxicity, and a potential for retained efficacy without the hallucinatory aspects of current psychedelic compounds.
  • Gain insights into the recent guidance issued by the US FDA and explore the regulatory pathways for the clinical study and approval of psychedelics in both Australia and the United States.

Our panel of scientists and clinicians from Australia and the US will provide invaluable insights into ongoing trials, innovations in psychedelic therapies, and the regulatory pathways shaping the future of mental health treatment.

Don’t miss this opportunity to stay informed about the latest developments in psychedelic research and regulatory advancements.

Secure your spot now for this enlightening webinar with Avance Clinical.

SPEAKERS:

Jorgen Mold, Senior Director of Scientific & Regulatory Services, Avance Clinical

Jorgen Mold is the Head of Scientific and Regulatory Affairs at Avance Clinical. Jorgen has worked within the clinical trial industry for over 25 years. Jorgen has prior experience as a Principal Scientific and Regulatory Affairs Specialist in a CRO environment. Additionally, Jorgen has prior experience in drug discovery and academic research positions at Northwestern University (USA), The University of Queensland and the Australian National University as well as 12 years in the biotechnology sector leading several ion channel/CNS drug discovery programs. Jorgen also spent four years working in medical affairs (neurology) at Merck Healthcare in Australia before joining Avance Clinical in August 2020.

Kevin Leach, Senior Vice President, Scientific & Regulatory Affairs, Avance Clinical

Kevin Leach has worked broadly in the biotechnology industry with hands-on experience in early and late-stage drug discovery and development. Through positions at Merck, Shire, Retrophin, Spring Bank, Quralis and Enveric as well as several other companies through consulting interactions, Kevin has worked in and led the ADME, toxicology, pharmacology, clinical pharmacology and bioanalysis functions.

Kevin has been responsible for leading discovery and development programs, the nominations of development candidates as well as multiple regulatory filings for molecules at the IND, BLA and NDA stages. He has also been part of teams that raised funding for public and private companies and has worked at mature and very early-stage companies with experience in many different indications and molecular platforms. Kevin is a member of the Boston Psychedelic Research Group and has worked on and led teams on multiple psychedelic compounds for psychiatric indications.

Kevin has recently joined Avance Clinical, an Australian and North American biotech specialist Clinical Research Organization as Senior Vice President of Scientific and Regulatory Affairs, based in Massachusetts, USA.

Who Should Attend?

This webinar will appeal to VPs, Directors, Managers, Department Heads, Scientists and Researchers working within the Biotech industry in the following areas:

  • Clinical affairs/Phase I unit
  • Clinical R&D/research
  • Clinical pharmacology/pharmacovigilance
  • Clinical operations/site selection and start-up/site management organization
  • Project management
  • Regulatory affairs
  • Medical affairs/medical research
  • Bioinformatics
  • Scientific affairs/study conduct
  • Business operations
  • Business development

What You Will Learn

Attendees will gain insights into:

  • Various psychoactive substances and promising therapeutic benefits for the treatment of psychiatric conditions
  • Explore the specific aspects of psychedelics crucial for orchestrating clinical trials
  • Examine the regulatory landscape governing novel psychedelic clinical studies in Australia
  • Delve into the outlook for emerging psychedelic compounds and their potential impact on the future

Register now!

Avance Clinical Finalist In The 61st Australian Export Awards 2023

By Other newsNo Comments

Adelaide, Australia | North Carolina, USAAvance Clinical, the award-winning Australian and North American market leading CRO for biotechs, has again been recognized for its contribution to International Health in the 61st Australian Export Awards 2023. 

The Australian Export Awards ceremony will be held on 30 November in Canberra at Parliament House. 

CEO Yvonne Lungershausen said, “Winning an Australian Export Award would be an incredible honor in recognition of Avance Clinical’s rapid growth, high quality service delivery and continued innovation in the clinical trials sector.” 

Avance Clinical’s primary focus is to find the best solutions for biotech’s drug development programs by offering deep scientific knowledge and execution experience. The companies agile and compliance-focused approach ensures the efficient access of medicines to patients with unmet needs.  

“We pride ourselves on being nimble and adaptive while focusing on operating to the highest standards of quality and compliance required by global regulatory agencies to ensure acceptance of data and subsequent drug approvals,” Ms Lungershausen said. 

Avance Clinical has experienced significant growth since being established in 2019, with its primary market being the United States, followed by Asia and Europe. Recently, the company established a North Carolina office, and a biometrics hub in Bangalore, India, to support its global biometrics team. 

“Avance Clinical now offers a specialized service, the GlobalReady program, which takes clients into Australia to commence their early phase clinical trials and reaps the benefits of the R&D Tax Rebate, and then seamlessly transitions them into the US for their later phase trials through Avance Clinical’s North American operations team,” she said. 

About Avance Clinical 

Avance Clinical is a full-service CRO for biotechs with a proven track-record for delivering clinical excellence in Australia, New Zealand, India and North America. As the largest premium full-service CRO in Australia and North America dedicated to biotechs, Avance Clinical specializes in delivering top-tier clinical trials that yield globally accepted data.  

Award-winning CRO for Biotechs 

Avance Clinical has been recognized for the fourth consecutive year by Frost & Sullivan in 2023, being awarded the Best Practices Customer Value Leadership for Biotech’s award, for its continuous exceptional performance. 

Pre-clinical through to Phase I and Beyond 

Avance Clinical offers pre-clinical consultancy services with their experienced ClinicReady team right through to Phase I and beyond clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes that are available in Australia. With experience across more than 110 therapeutic indications, Avance Clinical can deliver world-class, high-quality, internationally accepted data suitable for all major regulators, including FDA and EMA. 

Technology 

Avance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, Zelta, Veeva and Medrio are just some of Avance Clinical’s technology partners. 

Avance Clinical Invited To Brief 45 Korean Biotechs On Their Globalready Drug Development Pathway From Korea And Australia To The Us

By Company NewsNo Comments

Dt & SanoMedics Chairman, Charles Park (Park, Chae Gyoo) and Avance Clinical CEO Yvonne Lungershausen co-hosting the Global Clinical Trial Strategy Symposium in Korea last week.

Adelaide, Australia | North Carolina, USA – Avance Clinical, the Australian and North American market-leading CRO for biotechs, was asked to present their GlobalReady drug development solution to more than 45 Korean biotechs and pharmaceutical companies in Seoul, Korea last week as part of a special symposium at KoNECT Korea Conference. 

Avance Clinical’s Korean CRO partner Dt & SanoMedics initiated the Global Clinical Trial Strategy Symposium and invited Avance Clinical to co-host.

The Avance Clinical team, including CEO Yvonne Lungershausen, and Vice President, Commercial Business Development, Liahna Toy discussed drug development options including conducting clinical trials across South Korea, Australia, New Zealand, and the United States to support fast tracking clinical trial development programs.

Yvonne Lungershausen said Avance Clinical offers two critical solutions for biotechs.

“Avance Clinical in Australia can maximize the 43.5% rebate on clinical trial spend, and in the United States can provide high quality trials following the FDA pathway. Both approaches were received as attractive propositions for biotechs wanting to maximize their data captured and conserve funding,” she said.

“Our Avance Clinical teams in Australia and the United States offer world-class quality data and cultural alignment for Korean biotech clients designed to make their drug development programs seamless and successful.”

“Avance Clinical’s study data is accepted by all the main regulatory authorities including the MFDS and FDA; and conversely the Therapeutic Goods Administration (TGA) in Australia recognizes data generated in Korea.”

Yvonne Lungershausen thanked Korean CRO partner Dt & SanoMedics for arranging the Global Clinical Trial Strategy Symposium.

“This was an impressive group of biopharma companies and we are extremely excited to be part of their clinical program as they expand to the United States.”

“Thank you to Chairman of the Dt&C group, Charles Park and Yujin Lee, Vice-President of Dt & SanoMedics, and the entire team for welcoming and hosting Avance Clinical in South Korea.”

Dt & SanoMedics VP Yujin Lee said the partnership with Avance Clinical has been further strengthened with the team providing valuable international drug development strategies for the Korean biotech community.

“We are pleased to introduce the Avance Clinical team because we know they stand for quality. Importantly, they have the experience and track-record especially in the United States which is where most biotechs will be conducting their later phase trials.”

“We believe this has been an important visit which has enabled us to enhance our partnership and actively help Korean companies enter the US and Australian pharmaceutical markets,” she said.

About Avance Clinical

Avance Clinical is a full-service CRO for biotechs with a proven track-record for delivering clinical excellence in Australia, New Zealand, and North America. As the largest premium full-service CRO in Australia and North America, Avance Clinical specializes in delivering top-tier clinical trials that yield globally accepted data.

Award-winning CRO for Biotechs

Avance Clinical has been recognized for the fourth consecutive year by Frost & Sullivan in 2023, being awarded the Best Practices Customer Value Leadership for Biotech’s award, for its continuous exceptional performance.

Pre-clinical through to Phase I and Beyond

Avance Clinical offers pre-clinical consultancy services with their experienced ClinicReady team right through to Phase I and beyond clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes that are available in Australia and highly qualified sites and networks within the United States. With experience across more than 110 therapeutic indications, Avance Clinical can deliver world-class, high-quality, internationally accepted data suitable for FDA and EMA review.

Technology

Avance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, Zelta, Veeva and Medrio are just some of Avance Clinical’s technology partners.

Biotech CRO Leader, Avance Clinical, Backs California Life Sciences Entrepreneurship Program With Gold Sponsorship

By Company News, Other newsNo Comments

Adelaide, Australia | North Carolina, USA Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, is proud to announce its gold sponsorship of California Life Sciences (CLS) Innovation and Entrepreneurship programming.

Liahna Toy, Vice President, Commercial Business Development at Avance Clinical, said the sponsorship was an ideal way of supporting early phase biotech companies in California.

“Avance Clinical has been delivering clinical drug development services for biotechs for FDA and EMA regulatory approval, for more than two decades, with a significant client base located in the US.

“CLS is a life sciences membership organization, supporting companies of all sizes, from early-stage innovators and startups to established industry leaders in the fields of biotech, pharmaceuticals, and medical technology.

“Avance Clinical is very proud to be a Gold Sponsor of CLS to support early phase biotechs by providing insights and education around the benefits of commencing their early phase, healthy volunteer studies in Australia and the benefit of our GlobalReady program which focuses on taking biotechs from Phase I in Australia through to later phase studies in the US,” she said.

About Avance Clinical

Avance Clinical is a full-service CRO for biotechs with a proven track-record for delivering clinical excellence in Australia, New Zealand, and North America. As the largest premium full-service CRO in Australia and North America, Avance Clinical specializes in delivering top-tier clinical trials that yield globally accepted data.

Award-winning CRO for Biotechs

Avance Clinical has been recognized for the fourth consecutive year by Frost & Sullivan in 2023, being awarded the Best Practices Customer Value Leadership award, for its exceptional performance.

Pre-clinical through to Phase I and Beyond

Avance Clinical offers pre-clinical consultancy services with their experienced ClinicReady team right through to Phase I and beyond clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes that are available in Australia.

With experience across more than 110 therapeutic indications, Avance Clinical can deliver world-class, high-quality, internationally accepted data suitable for FDA and EMA review.

Technology

Avance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, Zelta, Veeva and Medrio are just some of Avance Clinical’s technology partners.

Avance Clinical Appoints US-Based Executives – SVP Scientific And Regulatory Affairs, And Director Business Development

By Company News, New Team MembersNo Comments

Adelaide, Australia | Raleigh, North Carolina, USA – Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, announces two key appointments in the US to support its continued global growth.

Kevin Leach joins as Senior Vice President of Scientific and Regulatory Affairs, based in Massachusetts, USA. Kevin has a background in the biopharma industry with experience in early and late-stage drug discovery and development.

Madison Esely-Kohlman has joined as a Director of Business Development based in Salt Lake City, Utah and is focused on partnering with biotech companies on their Phase I-III clinical trials.

In welcoming both Kevin and Madison, CEO, Yvonne Lungershausen said they bring significant expertise that will support Avance Clinical’s expanding US and Australian operations as well as our global growth plans.

“We are seeing increasing demand for our biotech-specific services such as ClinicReady and GlobalReady which are designed for pre-clinical, early phase and later phase clinical development. GlobalReady is a unique offering enabling biotechs to start rapidly and cost effectively with Avance Clinical in Australia and transition with our team in the US for later phase trials, with all the benefits of retaining the one CRO,” she said.

Kevin Leach PhD, DAB: Senior Vice President, Scientific and Regulatory Affairs

Kevin Leach has more than 20 years of experience working in drug discovery and development in the pharmaceutical industry and will provide exceptional knowledge and experience to Avance Clinical’s biotech clients. He has a PhD in biochemistry and molecular biophysics at Medical College of Virginia and completed his Post Doctoral Fellowship in Biological Engineering at Massachusetts Institute of Technology.

“Previously, I was on the client-side working with Avance Clinical. As we were considering the best CRO for our non-clinical and clinical programs Avance was consistently suggested to us as the premier partner in Australia. Once we started working together it was clear to me that the Avance team had a wealth of experience and expertise broadly in drug development and that we were in good hands at Avance.

“I joined Avance because I wanted to be part of an organization that was considered the gold standard in their field, and I felt comfortable that I would be working with highly intelligent, motivated, and experienced colleagues in our shared mission of bringing transformative medicines to patients.

“I am looking forward to applying my past experiences by working with the Avance team to enable sponsors developing diverse medicines of various molecular platforms, for different disease indications to deliver therapies that change and enrich the lives of the patients,” Kevin said.

Madison Esely-Kohlman: Director of Business Development

Madison Esely-Kohlman has considerable experience working in specialty drug development services, including in vitro DMPK testing and regulated bioanalysis, and GLP preclinical studies. Madison’s expertise includes engaging with clients early in their clinical development journey and supporting them into clinic. In her new role at Avance Clinical, she is looking forward to assisting clients navigate their clinical programs.

“Clinical trials bring not just tangible and thoroughly vetted medicines into the world; they can bring hope to families and individuals. Clinical trials run with expertise and efficiency mean faster access for those patients, and by joining Avance I am part of an organization dedicated to that outcome,” she said.

Madison is motivated by assisting US biotech companies to understand and take advantage of the benefits afforded by the Australian clinical pathway.

“A game-changer that really drew me to Avance Clinical as a CRO specifically is their ability to support sponsors in the longer term. The GlobalReady offering empowers our customers to maximize benefits of the Australian clinical network and transition into a global program with teams in the US and elsewhere in the world. My goal is to connect those companies to the resources and expertise available at Avance Clinical, so they have a trusted and capable partner in their programs,” Madison said.

Meet Madison in-person at COG West Coast on 7-8 November in Burlingame, CA.

About Avance Clinical

Avance Clinical is a full-service CRO for biotechs with a proven track-record for delivering clinical excellence in Australia, New Zealand, and North America. As the largest premium full-service CRO in Australia and North America, Avance Clinical specializes in delivering top-tier clinical trials that yield globally accepted data.

Award-winning CRO for Biotechs

Avance Clinical has been recognized for the fourth consecutive year by Frost & Sullivan in 2023, being awarded the Best Practices Customer Value Leadership for Biotech’s award, for its continuous exceptional performance.

Pre-clinical through to Phase I and Beyond

Avance Clinical offers pre-clinical consultancy services with their experienced ClinicReady team right through to Phase I and beyond clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes that are available in Australia. With experience across more than 110 therapeutic indications, Avance Clinical can deliver world-class, high-quality, internationally accepted data suitable for FDA and EMA review.

Technology

Avance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, Zelta, Veeva and Medrio are just some of Avance Clinical’s technology partners.

CEO Of Avance Clinical Nominated For Executive Of The Year In 2023 Citeline Pharma Intelligence Awards Japan

By Company Awards, Company NewsNo Comments

 

Adelaide, Australia | North Carolina, USA – Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, is proud to announce that Chief Executive Officer Yvonne Lungershausen has been nominated for Executive of the Year in the 2023 Citeline Pharma Intelligence Awards in Japan.

The Citeline Pharma Intelligence Award will be announced on October 17, 2023 in Tokyo. According to Citeline, the award, “is designed to acknowledge excellence in leadership, career achievements, influence within the industry and the key characteristics that make a good leader, such as decisive and clear strategy, team building and employee welfare.”

Avance Clinical has achieved outstanding success guided by Yvonne’s leadership, global vision and passion for quality and customer service. The company’s staff numbers have grown significantly by approximately 85% since Avance was established in 2019. In the last 12 months, Avance Clinical expanded its operations into the US, opened a North Carolina office and a new biometrics hub in Bangalore, India.

With her experience of over three decades in the Australian, New Zealand and US clinical trials drug development environment Yvonne has not only put Avance Clinical on the global map but hired and retained some of the best talents from across the globe.

Yvonne has helped champion a culture of innovation and adaptability within the company -successfully embracing emerging technologies and capitalizing on new market opportunities, hence strengthening its competitive position. Yvonne’s exceptional leadership has not only driven the company’s growth but has also positively impacted the lives of Avance Clinical’s employees, shareholders, and biotech clients.

She is highly regarded within the industry and is renowned for her exceptional expertise in addressing complex clinical trial challenges. She sees the importance of preparing for change fostering an adaptive and forward-thinking mindset within the organization. Her leadership is defined by a deep commitment to cultivating relationships and driving positive industry change.

CEO Yvonne Lungershausen said, “I am honored to be nominated for this award. It reflects not only my accomplishments as leader of the organization but our entire team’s efforts at Avance Clinical globally. Our team’s dedication and commitment to quality clinical research is what makes us so successful. We take pride in servicing the needs of our biotech clients and providing them with the very best, customized solutions.

“I am looking forward to attending the Citeline Pharma Intelligence awards ceremony in Tokyo in October – there is also the added benefit of being able to meet with and connect with our regional biotech clients,” she said.

 

About Avance Clinical

Avance Clinical is a full-service CRO for biotechs with a proven track-record for delivering clinical excellence in Australia, New Zealand, and North America. As the largest premium full-service CRO in Australia and North America, Avance Clinical specializes in delivering top-tier clinical trials that yield globally accepted data.

Award-winning CRO for Biotechs

Avance Clinical has been recognized for the fourth consecutive year by Frost & Sullivan in 2023, being awarded the Best Practices Customer Value Leadership for Biotech’s award, for its continuous exceptional performance.

Pre-clinical through to Phase I and Beyond

Avance Clinical offers pre-clinical consultancy services with their experienced ClinicReady team right through to Phase I and beyond clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes that are available in Australia. With experience across more than 110 therapeutic indications, Avance Clinical can deliver world-class, high-quality, internationally accepted data suitable for FDA and EMA review.

Technology

Avance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, Zelta, Veeva and Medrio are just some of Avance Clinical’s technology partners.

Join Avance Clinical In Seoul At KoNECT Korea 2023

By Company News, Conference NewsNo Comments

Adelaide, Australia | North Carolina, USA – Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, will visit Seoul in October to expand on collaborative opportunities with South Korean biotech companies. 

Avance Clinical’s delegation, including Chief Executive Officer Yvonne Lungershausen, Vice President, Commercial Business Development Liahna Toy, and Director of Business Development Cameron Williams, will participate in the prestigious KoNECT Korea Conference in Seoul, October 10-12 2023.

KoNECT Korea is a prestigious gathering of industry leaders, researchers, and innovators in the biotechnology and pharmaceutical sectors. This conference provides a unique platform for Avance Clinical to engage with South Korean biotech companies and experts, fostering collaborations and knowledge exchange.

Avance Clinical CEO Yvonne Lungershausen said they looked forward to expanding the company’s Korean client base and the opportunity to further establish and cultivate valuable relationships and connections with leading Korean biotech companies.

“We are looking forward to meeting with Korean biotechs to discuss the benefits of working with Avance Clinical,” commented Yvonne Lungershausen. “Korean biotechs can benefit from the Australian Advantage, which includes a fast start-up, no IND required, and up to 43.5% saving off clinical trial spend with the Australian R&D tax incentive.

“Korean biotechs then have access to the US via our US team based in North Carolina for later phase studies and ultimately FDA engagement,” she said.

“Avance Clinical’s Australian team has been supporting a number of Korean biotech companies through their clinical development programs offering a favorable regulatory environment, quality data, efficient processes, diverse patient populations, access to experts, stable political environment, strategic location, robust research infrastructure, and financial incentives. These factors collectively make Australia an attractive destination for biotech research and development.

“In fact, we are seeing increasing demand for our biotech specific services such as ClinicReady and GlobalReady which are designed for pre-clinical, early phase and later phase clinical development. GlobalReady is a unique offering enabling biotechs to start rapidly and cost effectively with Avance Clinical in Australia and transition with our team in the US for later phase trials, with all the benefits of retaining the one CRO,” she added.

Conference Information:

KoNECT Korea, October 10-12 2023 at the Conrad Hotel, Seoul, South Korea

https://avancecro.121group.dev/event/konect-korea/

Book a meeting with Avance Clinical:

https://www.konectintconference.org/web/Partnering/partneringRegistration.do

 

About Avance Clinical

Avance Clinical is a full-service CRO for biotechs with a proven track-record for delivering clinical excellence in Australia, New Zealand, and North America. As the largest premium full-service CRO in Australia and North America, Avance Clinical specializes in delivering top-tier clinical trials that yield globally accepted data.

Award-winning CRO for Biotechs

Avance Clinical has been recognized for the fourth consecutive year by Frost & Sullivan in 2023, being awarded the Best Practices Customer Value Leadership for Biotech’s award, for its continuous exceptional performance.

Pre-clinical through to Phase I and Beyond

Avance Clinical offers pre-clinical consultancy services with their experienced ClinicReady team right through to Phase I and beyond clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes that are available in Australia. With experience across more than 110 therapeutic indications, Avance Clinical can deliver world-class, high-quality, internationally accepted data suitable for FDA and EMA review.

Technology

Avance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, Zelta, Veeva and Medrio are just some of Avance Clinical’s technology partners.